A detailed history of Deka Bank Deutsche Girozentrale transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 40,745 shares of CRSP stock, worth $2.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,745
Previous 40,745 -0.0%
Holding current value
$2.08 Million
Previous $2.26 Million 3.53%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

BUY
$60.67 - $89.12 $45,199 - $66,394
745 Added 1.86%
40,745 $2.81 Million
Q2 2023

Jul 25, 2023

BUY
$43.47 - $67.77 $869,400 - $1.36 Million
20,000 Added 100.0%
40,000 $2.28 Million
Q1 2023

Apr 24, 2023

SELL
$41.0 - $56.12 $34,563 - $47,309
-843 Reduced 4.04%
20,000 $883,000
Q4 2022

Feb 01, 2023

BUY
$39.19 - $65.67 $33,037 - $55,359
843 Added 4.22%
20,843 $841,000
Q3 2022

Nov 02, 2022

SELL
$61.1 - $83.78 $1.57 Million - $2.15 Million
-25,660 Reduced 56.2%
20,000 $1.3 Million
Q1 2022

Apr 28, 2022

BUY
$53.19 - $79.24 $558,495 - $832,020
10,500 Added 29.86%
45,660 $2.93 Million
Q4 2021

Feb 02, 2022

SELL
$70.09 - $111.29 $1.1 Million - $1.74 Million
-15,650 Reduced 30.8%
35,160 $2.7 Million
Q3 2021

Oct 22, 2021

BUY
$110.2 - $156.64 $661,200 - $939,839
6,000 Added 13.39%
50,810 $5.6 Million
Q2 2021

Aug 05, 2021

BUY
$100.84 - $161.89 $857,140 - $1.38 Million
8,500 Added 23.41%
44,810 $6.74 Million
Q1 2021

Apr 28, 2021

BUY
$110.72 - $210.04 $2.21 Million - $4.2 Million
20,000 Added 122.62%
36,310 $4.18 Million
Q4 2020

Mar 12, 2021

BUY
$79.67 - $173.23 $227,856 - $495,437
2,860 Added 21.26%
16,310 $2.57 Million
Q3 2020

Oct 29, 2020

BUY
$78.5 - $100.64 $1.06 Million - $1.35 Million
13,450 New
13,450 $1.14 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.99B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.